Pharmacokinetics and safety of subcutaneous rituximab plus fludarabine and cyclophosphamide for patients with chronic lymphocytic leukaemia.
Identifieur interne : 002851 ( PubMed/Checkpoint ); précédent : 002850; suivant : 002852Pharmacokinetics and safety of subcutaneous rituximab plus fludarabine and cyclophosphamide for patients with chronic lymphocytic leukaemia.
Auteurs : Sarit Assouline [Canada] ; Valeria Buccheri [Brésil] ; Alain Delmer [France] ; Gianluca Gaidano [Italie] ; Christine Mcintyre [Royaume-Uni] ; Michael Brewster [Royaume-Uni] ; Olivier Catalani [Suisse] ; Florence Hourcade-Potelleret [Suisse] ; Pakeeza Sayyed [Suisse] ; Xavier Badoux [Australie]Source :
- British journal of clinical pharmacology [ 1365-2125 ] ; 2015.
Descripteurs français
- KwdFr :
- Administration par voie intraveineuse, Adulte, Adulte d'âge moyen, Calendrier d'administration des médicaments, Cyclophosphamide (administration et posologie), Cyclophosphamide (usage thérapeutique), Femelle, Humains, Injections sous-cutanées, Leucémie chronique lymphocytaire à cellules B (traitement médicamenteux), Mâle, Protocoles de polychimiothérapie antinéoplasique (administration et posologie), Protocoles de polychimiothérapie antinéoplasique (effets indésirables), Protocoles de polychimiothérapie antinéoplasique (pharmacocinétique), Préférence du patient, Rituximab (administration et posologie), Rituximab (effets indésirables), Rituximab (pharmacocinétique), Sujet âgé, Vidarabine (administration et posologie), Vidarabine (analogues et dérivés), Vidarabine (usage thérapeutique).
- MESH :
- administration et posologie : Cyclophosphamide, Protocoles de polychimiothérapie antinéoplasique, Rituximab, Vidarabine.
- analogues et dérivés : Vidarabine.
- effets indésirables : Protocoles de polychimiothérapie antinéoplasique, Rituximab.
- pharmacocinétique : Protocoles de polychimiothérapie antinéoplasique, Rituximab.
- traitement médicamenteux : Leucémie chronique lymphocytaire à cellules B.
- usage thérapeutique : Cyclophosphamide, Vidarabine.
- Administration par voie intraveineuse, Adulte, Adulte d'âge moyen, Calendrier d'administration des médicaments, Femelle, Humains, Injections sous-cutanées, Mâle, Préférence du patient, Sujet âgé.
English descriptors
- KwdEn :
- Administration, Intravenous, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols (administration & dosage), Antineoplastic Combined Chemotherapy Protocols (adverse effects), Antineoplastic Combined Chemotherapy Protocols (pharmacokinetics), Cyclophosphamide (administration & dosage), Cyclophosphamide (therapeutic use), Drug Administration Schedule, Female, Humans, Injections, Subcutaneous, Leukemia, Lymphocytic, Chronic, B-Cell (drug therapy), Male, Middle Aged, Patient Preference, Rituximab (administration & dosage), Rituximab (adverse effects), Rituximab (pharmacokinetics), Vidarabine (administration & dosage), Vidarabine (analogs & derivatives), Vidarabine (therapeutic use).
- MESH :
- chemical , administration & dosage : Cyclophosphamide, Rituximab, Vidarabine.
- administration & dosage : Antineoplastic Combined Chemotherapy Protocols.
- adverse effects : Antineoplastic Combined Chemotherapy Protocols, Rituximab.
- chemical , analogs & derivatives : Vidarabine.
- drug therapy : Leukemia, Lymphocytic, Chronic, B-Cell.
- pharmacokinetics : Antineoplastic Combined Chemotherapy Protocols, Rituximab.
- chemical , therapeutic use : Cyclophosphamide, Vidarabine.
- Administration, Intravenous, Adult, Aged, Drug Administration Schedule, Female, Humans, Injections, Subcutaneous, Male, Middle Aged, Patient Preference.
Abstract
The aim of the phase Ib, two part SAWYER study (BO25341; NCT01292603) was to investigate the pharmacokinetics and safety of subcutaneous (s.c.) rituximab compared with intravenous (i.v.) rituximab, both in combination with fludarabine and cyclophosphamide (FC), as first line treatment for patients with chronic lymphocytic leukaemia (CLL).
DOI: 10.1111/bcp.12662
PubMed: 25900065
Affiliations:
- Australie, Brésil, Canada, France, Italie, Royaume-Uni, Suisse
- Champagne-Ardenne, Grand Est, Québec
- Montréal, Reims
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:25900065Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Pharmacokinetics and safety of subcutaneous rituximab plus fludarabine and cyclophosphamide for patients with chronic lymphocytic leukaemia.</title><author><name sortKey="Assouline, Sarit" sort="Assouline, Sarit" uniqKey="Assouline S" first="Sarit" last="Assouline">Sarit Assouline</name><affiliation wicri:level="3"><nlm:affiliation>Jewish General Hospital, Montreal, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Jewish General Hospital, Montreal</wicri:regionArea><placeName><settlement type="city">Montréal</settlement><region type="state">Québec</region></placeName></affiliation></author><author><name sortKey="Buccheri, Valeria" sort="Buccheri, Valeria" uniqKey="Buccheri V" first="Valeria" last="Buccheri">Valeria Buccheri</name><affiliation wicri:level="1"><nlm:affiliation>Hematology Division, Hospital das Clinicas da Faculdade de Medicina da Universidade de Săo Paulo, Săo Paulo, Brazil.</nlm:affiliation><country xml:lang="fr">Brésil</country><wicri:regionArea>Hematology Division, Hospital das Clinicas da Faculdade de Medicina da Universidade de Săo Paulo, Săo Paulo</wicri:regionArea><wicri:noRegion>Săo Paulo</wicri:noRegion></affiliation></author><author><name sortKey="Delmer, Alain" sort="Delmer, Alain" uniqKey="Delmer A" first="Alain" last="Delmer">Alain Delmer</name><affiliation wicri:level="3"><nlm:affiliation>Hematologie Clinique, Hôpital Robert Debré, Reims, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Hematologie Clinique, Hôpital Robert Debré, Reims</wicri:regionArea><placeName><region type="region">Grand Est</region><region type="old region">Champagne-Ardenne</region><settlement type="city">Reims</settlement></placeName></affiliation></author><author><name sortKey="Gaidano, Gianluca" sort="Gaidano, Gianluca" uniqKey="Gaidano G" first="Gianluca" last="Gaidano">Gianluca Gaidano</name><affiliation wicri:level="1"><nlm:affiliation>Division of Hematology, Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont, Novara, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Division of Hematology, Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont, Novara</wicri:regionArea><wicri:noRegion>Novara</wicri:noRegion></affiliation></author><author><name sortKey="Mcintyre, Christine" sort="Mcintyre, Christine" uniqKey="Mcintyre C" first="Christine" last="Mcintyre">Christine Mcintyre</name><affiliation wicri:level="1"><nlm:affiliation>Roche Products Ltd, Welwyn Garden City, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Roche Products Ltd, Welwyn Garden City</wicri:regionArea><wicri:noRegion>Welwyn Garden City</wicri:noRegion></affiliation></author><author><name sortKey="Brewster, Michael" sort="Brewster, Michael" uniqKey="Brewster M" first="Michael" last="Brewster">Michael Brewster</name><affiliation wicri:level="1"><nlm:affiliation>Roche Products Ltd, Welwyn Garden City, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Roche Products Ltd, Welwyn Garden City</wicri:regionArea><wicri:noRegion>Welwyn Garden City</wicri:noRegion></affiliation></author><author><name sortKey="Catalani, Olivier" sort="Catalani, Olivier" uniqKey="Catalani O" first="Olivier" last="Catalani">Olivier Catalani</name><affiliation wicri:level="1"><nlm:affiliation>F. Hoffmann-La Roche Ltd, Basel, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>F. Hoffmann-La Roche Ltd, Basel</wicri:regionArea><wicri:noRegion>Basel</wicri:noRegion></affiliation></author><author><name sortKey="Hourcade Potelleret, Florence" sort="Hourcade Potelleret, Florence" uniqKey="Hourcade Potelleret F" first="Florence" last="Hourcade-Potelleret">Florence Hourcade-Potelleret</name><affiliation wicri:level="1"><nlm:affiliation>F. Hoffmann-La Roche Ltd, Basel, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>F. Hoffmann-La Roche Ltd, Basel</wicri:regionArea><wicri:noRegion>Basel</wicri:noRegion></affiliation></author><author><name sortKey="Sayyed, Pakeeza" sort="Sayyed, Pakeeza" uniqKey="Sayyed P" first="Pakeeza" last="Sayyed">Pakeeza Sayyed</name><affiliation wicri:level="1"><nlm:affiliation>F. Hoffmann-La Roche Ltd, Basel, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>F. Hoffmann-La Roche Ltd, Basel</wicri:regionArea><wicri:noRegion>Basel</wicri:noRegion></affiliation></author><author><name sortKey="Badoux, Xavier" sort="Badoux, Xavier" uniqKey="Badoux X" first="Xavier" last="Badoux">Xavier Badoux</name><affiliation wicri:level="1"><nlm:affiliation>Department of Haematology, St. George Hospital, Kogarah, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Department of Haematology, St. George Hospital, Kogarah</wicri:regionArea><wicri:noRegion>Kogarah</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2015">2015</date><idno type="RBID">pubmed:25900065</idno><idno type="pmid">25900065</idno><idno type="doi">10.1111/bcp.12662</idno><idno type="wicri:Area/PubMed/Corpus">002803</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002803</idno><idno type="wicri:Area/PubMed/Curation">002734</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002734</idno><idno type="wicri:Area/PubMed/Checkpoint">002734</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002734</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Pharmacokinetics and safety of subcutaneous rituximab plus fludarabine and cyclophosphamide for patients with chronic lymphocytic leukaemia.</title><author><name sortKey="Assouline, Sarit" sort="Assouline, Sarit" uniqKey="Assouline S" first="Sarit" last="Assouline">Sarit Assouline</name><affiliation wicri:level="3"><nlm:affiliation>Jewish General Hospital, Montreal, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Jewish General Hospital, Montreal</wicri:regionArea><placeName><settlement type="city">Montréal</settlement><region type="state">Québec</region></placeName></affiliation></author><author><name sortKey="Buccheri, Valeria" sort="Buccheri, Valeria" uniqKey="Buccheri V" first="Valeria" last="Buccheri">Valeria Buccheri</name><affiliation wicri:level="1"><nlm:affiliation>Hematology Division, Hospital das Clinicas da Faculdade de Medicina da Universidade de Săo Paulo, Săo Paulo, Brazil.</nlm:affiliation><country xml:lang="fr">Brésil</country><wicri:regionArea>Hematology Division, Hospital das Clinicas da Faculdade de Medicina da Universidade de Săo Paulo, Săo Paulo</wicri:regionArea><wicri:noRegion>Săo Paulo</wicri:noRegion></affiliation></author><author><name sortKey="Delmer, Alain" sort="Delmer, Alain" uniqKey="Delmer A" first="Alain" last="Delmer">Alain Delmer</name><affiliation wicri:level="3"><nlm:affiliation>Hematologie Clinique, Hôpital Robert Debré, Reims, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Hematologie Clinique, Hôpital Robert Debré, Reims</wicri:regionArea><placeName><region type="region">Grand Est</region><region type="old region">Champagne-Ardenne</region><settlement type="city">Reims</settlement></placeName></affiliation></author><author><name sortKey="Gaidano, Gianluca" sort="Gaidano, Gianluca" uniqKey="Gaidano G" first="Gianluca" last="Gaidano">Gianluca Gaidano</name><affiliation wicri:level="1"><nlm:affiliation>Division of Hematology, Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont, Novara, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Division of Hematology, Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont, Novara</wicri:regionArea><wicri:noRegion>Novara</wicri:noRegion></affiliation></author><author><name sortKey="Mcintyre, Christine" sort="Mcintyre, Christine" uniqKey="Mcintyre C" first="Christine" last="Mcintyre">Christine Mcintyre</name><affiliation wicri:level="1"><nlm:affiliation>Roche Products Ltd, Welwyn Garden City, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Roche Products Ltd, Welwyn Garden City</wicri:regionArea><wicri:noRegion>Welwyn Garden City</wicri:noRegion></affiliation></author><author><name sortKey="Brewster, Michael" sort="Brewster, Michael" uniqKey="Brewster M" first="Michael" last="Brewster">Michael Brewster</name><affiliation wicri:level="1"><nlm:affiliation>Roche Products Ltd, Welwyn Garden City, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Roche Products Ltd, Welwyn Garden City</wicri:regionArea><wicri:noRegion>Welwyn Garden City</wicri:noRegion></affiliation></author><author><name sortKey="Catalani, Olivier" sort="Catalani, Olivier" uniqKey="Catalani O" first="Olivier" last="Catalani">Olivier Catalani</name><affiliation wicri:level="1"><nlm:affiliation>F. Hoffmann-La Roche Ltd, Basel, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>F. Hoffmann-La Roche Ltd, Basel</wicri:regionArea><wicri:noRegion>Basel</wicri:noRegion></affiliation></author><author><name sortKey="Hourcade Potelleret, Florence" sort="Hourcade Potelleret, Florence" uniqKey="Hourcade Potelleret F" first="Florence" last="Hourcade-Potelleret">Florence Hourcade-Potelleret</name><affiliation wicri:level="1"><nlm:affiliation>F. Hoffmann-La Roche Ltd, Basel, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>F. Hoffmann-La Roche Ltd, Basel</wicri:regionArea><wicri:noRegion>Basel</wicri:noRegion></affiliation></author><author><name sortKey="Sayyed, Pakeeza" sort="Sayyed, Pakeeza" uniqKey="Sayyed P" first="Pakeeza" last="Sayyed">Pakeeza Sayyed</name><affiliation wicri:level="1"><nlm:affiliation>F. Hoffmann-La Roche Ltd, Basel, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>F. Hoffmann-La Roche Ltd, Basel</wicri:regionArea><wicri:noRegion>Basel</wicri:noRegion></affiliation></author><author><name sortKey="Badoux, Xavier" sort="Badoux, Xavier" uniqKey="Badoux X" first="Xavier" last="Badoux">Xavier Badoux</name><affiliation wicri:level="1"><nlm:affiliation>Department of Haematology, St. George Hospital, Kogarah, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Department of Haematology, St. George Hospital, Kogarah</wicri:regionArea><wicri:noRegion>Kogarah</wicri:noRegion></affiliation></author></analytic><series><title level="j">British journal of clinical pharmacology</title><idno type="eISSN">1365-2125</idno><imprint><date when="2015" type="published">2015</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Administration, Intravenous</term><term>Adult</term><term>Aged</term><term>Antineoplastic Combined Chemotherapy Protocols (administration & dosage)</term><term>Antineoplastic Combined Chemotherapy Protocols (adverse effects)</term><term>Antineoplastic Combined Chemotherapy Protocols (pharmacokinetics)</term><term>Cyclophosphamide (administration & dosage)</term><term>Cyclophosphamide (therapeutic use)</term><term>Drug Administration Schedule</term><term>Female</term><term>Humans</term><term>Injections, Subcutaneous</term><term>Leukemia, Lymphocytic, Chronic, B-Cell (drug therapy)</term><term>Male</term><term>Middle Aged</term><term>Patient Preference</term><term>Rituximab (administration & dosage)</term><term>Rituximab (adverse effects)</term><term>Rituximab (pharmacokinetics)</term><term>Vidarabine (administration & dosage)</term><term>Vidarabine (analogs & derivatives)</term><term>Vidarabine (therapeutic use)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Administration par voie intraveineuse</term><term>Adulte</term><term>Adulte d'âge moyen</term><term>Calendrier d'administration des médicaments</term><term>Cyclophosphamide (administration et posologie)</term><term>Cyclophosphamide (usage thérapeutique)</term><term>Femelle</term><term>Humains</term><term>Injections sous-cutanées</term><term>Leucémie chronique lymphocytaire à cellules B (traitement médicamenteux)</term><term>Mâle</term><term>Protocoles de polychimiothérapie antinéoplasique (administration et posologie)</term><term>Protocoles de polychimiothérapie antinéoplasique (effets indésirables)</term><term>Protocoles de polychimiothérapie antinéoplasique (pharmacocinétique)</term><term>Préférence du patient</term><term>Rituximab (administration et posologie)</term><term>Rituximab (effets indésirables)</term><term>Rituximab (pharmacocinétique)</term><term>Sujet âgé</term><term>Vidarabine (administration et posologie)</term><term>Vidarabine (analogues et dérivés)</term><term>Vidarabine (usage thérapeutique)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Cyclophosphamide</term><term>Rituximab</term><term>Vidarabine</term></keywords><keywords scheme="MESH" qualifier="administration & dosage" xml:lang="en"><term>Antineoplastic Combined Chemotherapy Protocols</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Cyclophosphamide</term><term>Protocoles de polychimiothérapie antinéoplasique</term><term>Rituximab</term><term>Vidarabine</term></keywords><keywords scheme="MESH" qualifier="adverse effects" xml:lang="en"><term>Antineoplastic Combined Chemotherapy Protocols</term><term>Rituximab</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Vidarabine</term></keywords><keywords scheme="MESH" qualifier="analogues et dérivés" xml:lang="fr"><term>Vidarabine</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Leukemia, Lymphocytic, Chronic, B-Cell</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Protocoles de polychimiothérapie antinéoplasique</term><term>Rituximab</term></keywords><keywords scheme="MESH" qualifier="pharmacocinétique" xml:lang="fr"><term>Protocoles de polychimiothérapie antinéoplasique</term><term>Rituximab</term></keywords><keywords scheme="MESH" qualifier="pharmacokinetics" xml:lang="en"><term>Antineoplastic Combined Chemotherapy Protocols</term><term>Rituximab</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Cyclophosphamide</term><term>Vidarabine</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Leucémie chronique lymphocytaire à cellules B</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Cyclophosphamide</term><term>Vidarabine</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Administration, Intravenous</term><term>Adult</term><term>Aged</term><term>Drug Administration Schedule</term><term>Female</term><term>Humans</term><term>Injections, Subcutaneous</term><term>Male</term><term>Middle Aged</term><term>Patient Preference</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Administration par voie intraveineuse</term><term>Adulte</term><term>Adulte d'âge moyen</term><term>Calendrier d'administration des médicaments</term><term>Femelle</term><term>Humains</term><term>Injections sous-cutanées</term><term>Mâle</term><term>Préférence du patient</term><term>Sujet âgé</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The aim of the phase Ib, two part SAWYER study (BO25341; NCT01292603) was to investigate the pharmacokinetics and safety of subcutaneous (s.c.) rituximab compared with intravenous (i.v.) rituximab, both in combination with fludarabine and cyclophosphamide (FC), as first line treatment for patients with chronic lymphocytic leukaemia (CLL).</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">25900065</PMID><DateCreated><Year>2015</Year><Month>10</Month><Day>28</Day></DateCreated><DateCompleted><Year>2016</Year><Month>09</Month><Day>12</Day></DateCompleted><DateRevised><Year>2016</Year><Month>12</Month><Day>15</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1365-2125</ISSN><JournalIssue CitedMedium="Internet"><Volume>80</Volume><Issue>5</Issue><PubDate><Year>2015</Year><Month>Nov</Month></PubDate></JournalIssue><Title>British journal of clinical pharmacology</Title><ISOAbbreviation>Br J Clin Pharmacol</ISOAbbreviation></Journal><ArticleTitle>Pharmacokinetics and safety of subcutaneous rituximab plus fludarabine and cyclophosphamide for patients with chronic lymphocytic leukaemia.</ArticleTitle><Pagination><MedlinePgn>1001-9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/bcp.12662</ELocationID><Abstract><AbstractText Label="AIMS" NlmCategory="OBJECTIVE">The aim of the phase Ib, two part SAWYER study (BO25341; NCT01292603) was to investigate the pharmacokinetics and safety of subcutaneous (s.c.) rituximab compared with intravenous (i.v.) rituximab, both in combination with fludarabine and cyclophosphamide (FC), as first line treatment for patients with chronic lymphocytic leukaemia (CLL).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">During part 1 (dose-finding), CLL patients received rituximab i.v. followed by a single dose of rituximab s.c. at one of three fixed doses (1400, 1600 or 1870 mg) in cycle 6. The primary objective was to identify a fixed s.c. dose that would achieve comparable rituximab serum trough concentrations (Ctrough ) to those achieved with the standard 4 weekly 500 mg m(-2) rituximab i.v. dose.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Fifty-five patients received a fixed dose of rituximab s.c., 16 received 1400 mg, 17 received 1600 mg and 22 received 1870 mg. The 1600 mg dose was predicted to achieve non-inferior Ctrough to standard rituximab i.v.</AbstractText><AbstractText Label="TREATMENT" NlmCategory="METHODS">The rituximab s.c. safety profile was comparable with rituximab i.v., except that local administration-related reactions, mainly mild/moderate injection site reactions, occurred more frequently with rituximab s.c., which was not unexpected. Subcutaneous administration was preferred to i.v. administration by >90% of patients and nurses (n = 112).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">SAWYER part 1 data predict that rituximab s.c. 1600 mg will achieve non-inferior Ctrough concentrations to rituximab i.v. 500 mg m(-2) , administered 4 weekly. This fixed s.c. dose is currently undergoing formal non-inferiority assessment in SAWYER part 2. In future, CLL treatment regimens comprising rituximab s.c. and oral FC could substantially reduce i.v. chair time.</AbstractText><CopyrightInformation>© 2015 The British Pharmacological Society.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Assouline</LastName><ForeName>Sarit</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Jewish General Hospital, Montreal, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Buccheri</LastName><ForeName>Valeria</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Hematology Division, Hospital das Clinicas da Faculdade de Medicina da Universidade de Săo Paulo, Săo Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Delmer</LastName><ForeName>Alain</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Hematologie Clinique, Hôpital Robert Debré, Reims, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gaidano</LastName><ForeName>Gianluca</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Division of Hematology, Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont, Novara, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McIntyre</LastName><ForeName>Christine</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Roche Products Ltd, Welwyn Garden City, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brewster</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Roche Products Ltd, Welwyn Garden City, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Catalani</LastName><ForeName>Olivier</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>F. Hoffmann-La Roche Ltd, Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hourcade-Potelleret</LastName><ForeName>Florence</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>F. Hoffmann-La Roche Ltd, Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sayyed</LastName><ForeName>Pakeeza</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>F. Hoffmann-La Roche Ltd, Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Badoux</LastName><ForeName>Xavier</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Haematology, St. George Hospital, Kogarah, Australia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT01292603</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D017426">Clinical Trial, Phase I</PublicationType><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>07</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Br J Clin Pharmacol</MedlineTA><NlmUniqueID>7503323</NlmUniqueID><ISSNLinking>0306-5251</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>4F4X42SYQ6</RegistryNumber><NameOfSubstance UI="D000069283">Rituximab</NameOfSubstance></Chemical><Chemical><RegistryNumber>8N3DW7272P</RegistryNumber><NameOfSubstance UI="D003520">Cyclophosphamide</NameOfSubstance></Chemical><Chemical><RegistryNumber>FA2DM6879K</RegistryNumber><NameOfSubstance UI="D014740">Vidarabine</NameOfSubstance></Chemical><Chemical><RegistryNumber>P2K93U8740</RegistryNumber><NameOfSubstance UI="C024352">fludarabine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2009 Aug 20;27(24):3994-4001</RefSource><PMID Version="1">19597025</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Pharmacol. 2009 Sep;49(9):1012-24</RefSource><PMID Version="1">19620385</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Pain Symptom Manage. 2009 Nov;38(5):663-72</RefSource><PMID Version="1">19819665</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Curr Med Res Opin. 2010 Feb;26(2):279-88</RefSource><PMID Version="1">19947907</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet. 2010 Oct 2;376(9747):1164-74</RefSource><PMID Version="1">20888994</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet Oncol. 2012 Sep;13(9):869-78</RefSource><PMID Version="1">22884505</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Arzneimittelforschung. 2012 Sep;62(9):401-9</RefSource><PMID Version="1">22918857</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Pharmacol. 2012 Dec;52(12):1918-26</RefSource><PMID Version="1">22235140</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Pharmacol. 2013 Feb;53(2):192-201</RefSource><PMID Version="1">23436264</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet Oncol. 2013 Sep;14(10):962-70</RefSource><PMID Version="1">23965225</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet Oncol. 2014 Mar;15(3):343-52</RefSource><PMID Version="1">24521993</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2014 Jun 10;32(17):1782-91</RefSource><PMID Version="1">24821885</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Semin Oncol. 2000 Dec;27(6 Suppl 12):86-90</RefSource><PMID Version="1">11226005</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2001 Apr 15;19(8):2165-70</RefSource><PMID Version="1">11304768</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Blood. 2002 Aug 1;100(3):768-73</RefSource><PMID Version="1">12130484</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Control Release. 2006 Aug 28;114(2):230-41</RefSource><PMID Version="1">16876899</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Expert Opin Drug Deliv. 2007 Jul;4(4):427-40</RefSource><PMID Version="1">17683255</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Blood. 2008 Jun 15;111(12):5446-56</RefSource><PMID Version="1">18216293</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D061605" MajorTopicYN="N">Administration, Intravenous</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000971" MajorTopicYN="N">Antineoplastic Combined Chemotherapy Protocols</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003520" MajorTopicYN="N">Cyclophosphamide</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004334" MajorTopicYN="N">Drug Administration Schedule</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007279" MajorTopicYN="N">Injections, Subcutaneous</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015451" MajorTopicYN="N">Leukemia, Lymphocytic, Chronic, B-Cell</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057240" MajorTopicYN="N">Patient Preference</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069283" MajorTopicYN="N">Rituximab</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000493" MajorTopicYN="Y">pharmacokinetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014740" MajorTopicYN="N">Vidarabine</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000031" MajorTopicYN="Y">analogs & derivatives</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><OtherID Source="NLM">PMC4631173 [Available on 11/01/16]</OtherID><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">chronic lymphocytic leukaemia</Keyword><Keyword MajorTopicYN="N">cyclophosphamide</Keyword><Keyword MajorTopicYN="N">fludarabine</Keyword><Keyword MajorTopicYN="N">pharmacokinetics</Keyword><Keyword MajorTopicYN="N">rituximab</Keyword><Keyword MajorTopicYN="N">subcutaneous</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>05</Month><Day>09</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2015</Year><Month>03</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>04</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>4</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>4</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>9</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25900065</ArticleId><ArticleId IdType="doi">10.1111/bcp.12662</ArticleId><ArticleId IdType="pmc">PMC4631173</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Australie</li><li>Brésil</li><li>Canada</li><li>France</li><li>Italie</li><li>Royaume-Uni</li><li>Suisse</li></country><region><li>Champagne-Ardenne</li><li>Grand Est</li><li>Québec</li></region><settlement><li>Montréal</li><li>Reims</li></settlement></list><tree><country name="Canada"><region name="Québec"><name sortKey="Assouline, Sarit" sort="Assouline, Sarit" uniqKey="Assouline S" first="Sarit" last="Assouline">Sarit Assouline</name></region></country><country name="Brésil"><noRegion><name sortKey="Buccheri, Valeria" sort="Buccheri, Valeria" uniqKey="Buccheri V" first="Valeria" last="Buccheri">Valeria Buccheri</name></noRegion></country><country name="France"><region name="Grand Est"><name sortKey="Delmer, Alain" sort="Delmer, Alain" uniqKey="Delmer A" first="Alain" last="Delmer">Alain Delmer</name></region></country><country name="Italie"><noRegion><name sortKey="Gaidano, Gianluca" sort="Gaidano, Gianluca" uniqKey="Gaidano G" first="Gianluca" last="Gaidano">Gianluca Gaidano</name></noRegion></country><country name="Royaume-Uni"><noRegion><name sortKey="Mcintyre, Christine" sort="Mcintyre, Christine" uniqKey="Mcintyre C" first="Christine" last="Mcintyre">Christine Mcintyre</name></noRegion><name sortKey="Brewster, Michael" sort="Brewster, Michael" uniqKey="Brewster M" first="Michael" last="Brewster">Michael Brewster</name></country><country name="Suisse"><noRegion><name sortKey="Catalani, Olivier" sort="Catalani, Olivier" uniqKey="Catalani O" first="Olivier" last="Catalani">Olivier Catalani</name></noRegion><name sortKey="Hourcade Potelleret, Florence" sort="Hourcade Potelleret, Florence" uniqKey="Hourcade Potelleret F" first="Florence" last="Hourcade-Potelleret">Florence Hourcade-Potelleret</name><name sortKey="Sayyed, Pakeeza" sort="Sayyed, Pakeeza" uniqKey="Sayyed P" first="Pakeeza" last="Sayyed">Pakeeza Sayyed</name></country><country name="Australie"><noRegion><name sortKey="Badoux, Xavier" sort="Badoux, Xavier" uniqKey="Badoux X" first="Xavier" last="Badoux">Xavier Badoux</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002851 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 002851 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:25900065
|texte= Pharmacokinetics and safety of subcutaneous rituximab plus fludarabine and cyclophosphamide for patients with chronic lymphocytic leukaemia.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:25900065" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |